Joint-focused · Dual-modality
BioFusion
Wharton's Jelly stem cell joint therapy, now paired with 50 billion exosomes in the same joint treatment. Same proven foundation — meaningfully more complete.
- Structural support and cellular signaling in one unified protocol
- Designed specifically for joint and soft-tissue environments
- Available for joint injections only



